Dr Dahlia Salman
CEO
Bioxhale's Co-founder and CEO, Dahlia Salman, has an extensive experience in breath analysis for clinical diagnostic applications. Dahlia's passion and focus on medical applications of breath testing for early disease detection comes from her personal experiences. She worked closely with clinical partners, in Leicester, Edinburgh, Norway and Sri Lanka, who integrated breath testing across a range of clinical studies. These include early detection of asthma, COPD, pneumonia and heart failure as part of the EMBER consortium. She also worked very closely with clinical and analytical scientists, within the TOXI-Triage project, to discover biomarkers for precision medicine applications for prostate cancer patients receiving radiation therapy. She has raised >£350K 2019-2022 to develop breath sampling technologies from her accomplishments in clinical breath-research. Bioxhale Ltd is developing the next-generation non-invasive breaths sampling technologies to support early disease detection and precision medicine at the point-of-care settings.
Dr Stephen Little
Business Advisor
Dr Stephen Little is Bioxhale's business advisor, he has been working very closely with the co-founders to shape the company's business development. Steve was the CEO of DxS and pioneered development and manufacture of companion diagnostics for personalised medicine. Steve became Vice Chair of YourGene (2021-revenue £37.6M). At Bioxhale Steve is providing support for commercialisation, growth, and investor relationships.
Prof Paul Thomas
CSO
Bioxhale's Co-founder and CSO, Paul Thomas, has led research in ultra-trace volatiles in complex-systems since 1985, and is an international authority in breath, saliva, and skin volatilomic analysis for diagnostics and emergency-care applications.
Paul has raised substantial funds for, and directed, large international consortia, serves on the boards of international research organisations. He has acted as science advisor to UK Gov Cabinet office and MHRA.
Prior to Bioxhale, Paul was leading the multi-million-pound TOXI-Triage project, which brought together experts from across Europe to create novel ways to give effective and diagnostically sound medical and toxic assessments to the casualties of a CBRN event amid the confusion, disorder, and dangers it can bring.
At Bioxhale, he is responsible for analytical quality-by-design, breath-sampling systems innovation/development, validation of enhanced features and analytical operational concepts.
Prof Chris Brightling
Clinical Director
Bioxhale's Co-founder and Clinical Director, Chris Brightling, is a senior NIHR investigator; respiratory theme lead for Leicester NIHR Biomedical Research Centre; member of the scientific committee for the Global Initiative for Asthma – GINA; the current ERS Science Council Chair; and, UK national lead for the post-COVID consortium PHOSP-COVID. Chris was leading the East Midlands Breathomics Pathology Node (EMBER) which was funded by the Medical Research Council (MRC) and Engineering and Physical Sciences Research Council (EPSRC) and hosted by the NIHR Leicester Biomedical Research Centre. At Bioxhale, Chris is responsible for clinical-studies, health-economics, care-pathways, pharmaceutical relationships/networks and companion-diagnostics development.